Analysts Set Bausch Health Companies Inc. (NYSE:BHC) PT at $7.42

Bausch Health Companies Inc. (NYSE:BHC) has received an average rating of “Reduce” from the seven research firms that are currently covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation and six have given a hold recommendation to the company. The average 1-year target price among brokerages that have updated their coverage on the stock in the last year is $7.42.

BHC has been the topic of a number of recent analyst reports. StockNews.com upgraded Bausch Health Companies from a “hold” rating to a “buy” rating in a report on Friday, October 25th. Royal Bank of Canada dropped their price target on Bausch Health Companies from $11.00 to $10.00 and set a “sector perform” rating on the stock in a report on Thursday, January 30th. Finally, Jefferies Financial Group reiterated a “hold” rating and set a $8.00 price target (down from $12.00) on shares of Bausch Health Companies in a report on Thursday, February 6th.

Institutional Investors Weigh In On Bausch Health Companies

Several hedge funds have recently added to or reduced their stakes in BHC. Mountain Hill Investment Partners Corp. bought a new stake in Bausch Health Companies during the fourth quarter worth about $56,000. Tobam lifted its stake in Bausch Health Companies by 10.4% during the fourth quarter. Tobam now owns 15,034 shares of the company’s stock worth $121,000 after purchasing an additional 1,422 shares during the last quarter. Norges Bank bought a new stake in Bausch Health Companies during the fourth quarter worth about $141,000. DGS Capital Management LLC bought a new stake in Bausch Health Companies during the fourth quarter worth about $143,000. Finally, Kendall Capital Management lifted its stake in Bausch Health Companies by 43.4% during the fourth quarter. Kendall Capital Management now owns 17,995 shares of the company’s stock worth $145,000 after purchasing an additional 5,445 shares during the last quarter. Institutional investors own 78.65% of the company’s stock.

Bausch Health Companies Stock Performance

Shares of NYSE:BHC opened at $6.36 on Monday. The business’s 50 day simple moving average is $7.55 and its two-hundred day simple moving average is $7.45. The firm has a market cap of $2.30 billion, a P/E ratio of -13.25, a PEG ratio of 0.34 and a beta of 0.68. Bausch Health Companies has a 52-week low of $3.96 and a 52-week high of $11.46.

About Bausch Health Companies

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.